Clinical data | |
---|---|
Pronunciation | /ˌflʊroʊˈjʊrəˌsɪl/ |
Trade names | Adrucil, Carac, Efudex, Efudix, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682708 |
License data |
|
Pregnancy category |
|
Routes of administration |
IV (infusion or ) and topical |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 28 to 100% |
Protein binding | 8 to 12% |
Metabolism | Intracellular and liver (-mediated) |
Biological half-life | 16 minutes |
Excretion | kidney |
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
ECHA InfoCard | 100.000.078 |
Chemical and physical data | |
Formula | C4H3FN2O2 |
Molar mass | 130.077 g/mol |
3D model (Jmol) | |
Melting point | 282–283 °C (540–541 °F) |
|
|
|
|
Fluorouracil (5-FU), sold under the brand name Adrucil among others, is a medication used to treat cancer. By injection into a vein it is used for colon cancer, esophageal cancer, stomach cancer, pancreatic cancer, breast cancer, and cervical cancer. As a cream it is used for actinic keratosis and basal cell carcinoma.
When used by injection most people develop side effects. Common side effects include inflammation of the mouth, loss of appetite, low blood cell counts, hair loss, and inflammation of the skin. When used as a cream irritation at the site of application may occur. Use of either form in pregnancy may harm the baby. Fluorouracil is in the antimetabolite and pyrimidine analog families of medications. How it works is not entirely clear but believed to involve blocking the action of thymidylate synthase and thus stopping the production of DNA.
Fluorouracil was patented in 1956 and came into medical use in 1962. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is about 1.18 to 3.40 USD per 500 mg vial. In the United Kingdom this amount costs the NHS about 6.40 pounds.
Fluorouracil has been given systemically for anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers). It has also been given topically (on the skin) for actinic keratoses, skin cancers and Bowen's disease and as eye drops for treatment of ocular surface squamous neoplasia.